Minireviews
Copyright ©The Author(s) 2021. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Gastroenterol. Sep 14, 2021; 27(34): 5700-5714
Published online Sep 14, 2021. doi: 10.3748/wjg.v27.i34.5700
Updates in diagnosis and management of pancreatic cysts
Linda S Lee
Linda S Lee, Division of Gastroenterology, Hepatology and Endoscopy, Brigham and Women's Hospital, Boston, MA 02115, United States
Author contributions: Lee LS is sole author of this review.
Conflict-of-interest statement: No conflict of interest.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Linda S Lee, MD, Associate Professor, Director, Division of Gastroenterology, Hepatology and Endoscopy, Brigham and Women's Hospital, 75 Francis St, Boston, MA 02115, United States. llee@bwh.harvard.edu
Received: February 28, 2021
Peer-review started: February 28, 2021
First decision: April 18, 2021
Revised: May 14, 2021
Accepted: August 20, 2021
Article in press: August 20, 2021
Published online: September 14, 2021
Abstract

Incidental pancreatic cysts are commonly encountered with some cysts having malignant potential. The most common pancreatic cystic neoplasms include serous cystadenoma, mucinous cystic neoplasm and intraductal papillary mucinous neoplasm. Risk stratifying pancreatic cysts is important in deciding whether patients may benefit from endoscopic ultrasound (EUS) or surgical resection. Surgery should be reserved for patients with malignant cysts or cysts at high risk for developing malignancy as suggested by various risk features including solid mass, nodule and dilated main pancreatic duct. EUS may supplement magnetic resonance imaging findings for cysts that remain indeterminate or have concerning features on imaging. Various cyst fluid markers including carcinoembryonic antigen, glucose, amylase, cytology, and DNA markers help distinguish mucinous from nonmucinous cysts. This review will guide the practicing gastroenterologist in how to evaluate incidental pancreatic cysts and when to consider referral for EUS or surgery. For presumed low risk cysts, surveillance strategies will be discussed. Managing pancreatic cysts requires an individualized approach that is directed by the various guidelines.

Keywords: Pancreatic cyst, Intraductal papillary mucinous neoplasm, Endoscopic ultrasound-guided fine needle aspiration, Serous cystadenoma, Surveillance, Carcinoembryonic antigen

Core Tip: Incidental pancreatic cysts are common, and some have malignant potential. magnetic resonance imaging of the pancreas should be used to risk stratify pancreatic cysts and decide whether patients may benefit from endoscopic ultrasound or surgical resection. Presumed low risk cysts should undergo surveillance unless the patient is not a surgical candidate or has a pseudocyst or serous cystadenoma. We discuss the approach to diagnosis and management of incidental pancreatic cysts.